Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.40 |
| ▸ | METAP1 | P53582 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 4/20 | 0.38 |
| ▸ | MME | P08473 | 3/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
| ▸ | PYGM | P11217 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998445 | 1.00 | RIPK1 (0.40) | RIPK1METAP1ACEMMEXIAP | |
| SCHEMBL12569127 | 1.00 | RIPK1 (0.40) | RIPK1METAP1ACEMMEXIAP | |
| SCHEMBL2001076 | 0.89 | RIPK1 (0.40) | RIPK1METAP1ACEMMEXIAP | |
| SCHEMBL2001079 | 0.89 | RIPK1 (0.40) | RIPK1METAP1ACEMMEXIAP | |
| SCHEMBL12569134 | 0.89 | RIPK1 (0.40) | RIPK1METAP1ACEMMEXIAP | |
| SCHEMBL12569138 | 0.88 | RIPK1 (0.44) | RIPK1METAP1ACEMMEXIAP | |
| SCHEMBL1997047 | 0.88 | RIPK1 (0.44) | RIPK1METAP1ACEMMEXIAP | |
| SCHEMBL1997050 | 0.88 | RIPK1 (0.44) | RIPK1METAP1ACEMMEXIAP | |
| SCHEMBL1997611 | 0.85 | METAP1 (0.57) | RIPK1METAP1ACEMMEXIAP | |
| SCHEMBL1993833 | 0.85 | METAP1 (0.57) | RIPK1METAP1ACEMMEXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960373-B2 | 2-alkoxy-3,4,5-trihydroxyalkylamide-benzothiazepines preparation thereof, compositions containing them and use thereof | SANOFI-AVENTIS (FR) | 2011-06-14 | — | — | US | claimed |
| EP-2029596-B1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZOTHIAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI AVENTIS (FR) | 2010-02-24 | — | — | EP | claimed |
| US-20090093459-A1 | 2-ALKOXY-3,4,5-TRIHYDROXYALKYLAMIDE-BENZOTHIAZEPINES PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | claimed |
| US-7960373-B2 | 2-alkoxy-3,4,5-trihydroxyalkylamide-benzothiazepines preparation thereof, compositions containing them and use thereof | SANOFI-AVENTIS (FR) | 2011-06-14 | — | — | US | disclosed |
| US-7960373-B2 | 2-alkoxy-3,4,5-trihydroxyalkylamide-benzothiazepines preparation thereof, compositions containing them and use thereof | SANOFI-AVENTIS (FR) | 2011-06-14 | — | — | US | disclosed |
| US-7960373-B2 | 2-alkoxy-3,4,5-trihydroxyalkylamide-benzothiazepines preparation thereof, compositions containing them and use thereof | SANOFI-AVENTIS (FR) | 2011-06-14 | — | — | US | disclosed |
| EP-2029596-B1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZOTHIAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI AVENTIS (FR) | 2010-02-24 | — | — | EP | disclosed |
| US-20090093459-A1 | 2-ALKOXY-3,4,5-TRIHYDROXYALKYLAMIDE-BENZOTHIAZEPINES PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093459-A1 | 2-ALKOXY-3,4,5-TRIHYDROXYALKYLAMIDE-BENZOTHIAZEPINES PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093459-A1 | 2-ALKOXY-3,4,5-TRIHYDROXYALKYLAMIDE-BENZOTHIAZEPINES PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| WO-2007135294-A2 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDE-BENZOTHIAZEPINES, THE PREPARATION AND USE THEREOF, AND COMPOSITIONS CONTAINING THE SAME | SANOFI-AVENTIS (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093459-A1 | 2-ALKOXY-3,4,5-TRIHYDROXYALKYLAMIDE-BENZOTHIAZEPINES PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | TPH2, CYP4B1, HTR3C | RIPK1 4672/4885METAP1 3151/4885ACE 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.